AddLife AB operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares AddLife AB with three other
miscellaneous service companies in Europe:
of UNITED KINGDOM
sales of £488.50 million [US$650.47 million]
of which 52%
was Operating Genus PIC),
Bachem Holding AG
(313.72 million Swiss Francs [US$343.61 million]
of which 88%
was Active Pharmaceutical Ingredients), and
GW Pharmaceuticals PLC
based in UNITED KINGDOM
(£243.39 million [US$324.09 million]
of which 100%
was Novel Therapeutics).
AddLife AB reported sales of SEK 3.48 billion (US$403.12 million)
December of 2019.
increase of 40.2%
versus 2018, when the company's sales were SEK 2.48 billion.
Sales at AddLife AB have increased during each of the previous five years
(and since 2014, sales have increased a total of 254%).
Sales of Medtech saw an increase
45.4% in 2019, from
SEK 1.03 billion to SEK 1.50 billion.